tgAAC 94

N/A

Report date: 2023/10/26 16:50:50

Base Information

Drug NametgAAC 94
Drug Alias NameTNFR:Fc gene therapytgAAV-TNFR:FcrAAV2-TNFR:FctgAAC11tgAAC94
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionGene transferenceTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPeriodontal DiseasesArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArmata Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArmata Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPeriodontal DiseasesArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A